Rosai-Dorfman Disease clinical trials at UCSF

1 research study open to eligible people

Rosai-Dorfman disease is a rare disease marked by large lymph nodes and immune cell buildup. UCSF is enrolling children and adults to study the effects of cobimetinib on histiocytic conditions. UCSF is recording scans, lab tests, and side effects during treatment.

Showing trials for

  • Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

    open to all eligible people

    This is a research study of a drug called cobimetinib in children and adults diagnosed with Langerhans cell histiocytosis (LCH), and other histiocytic disorders that has returned or does not respond to treatment. Cobimetinib blocks activation of a protein called Mitogen-activated protein kinase (MEK) that is part of incorrect growth signals in histiocytosis cells. Four different groups of patients will be enrolled.

    San Francisco, California and other locations

Our lead scientists for Rosai-Dorfman Disease research studies include .

Last updated: